Ziad joined Biomodex in 2019. He has served as President and CEO since 2020. Ziad has over 20 years in the medical device industry. Prior to joining Biomodex, Ziad served as Vice-President of Regulatory and clinical Affairs at JUUL Labs (Altria acquisition). Previously, he served as Vice President, Pre-clinical, Regulatory and Clinical Affairs for PQ Bypass (Fogardy Institute for Innovation incubation). Ziad further served as Vice President, Pre-clinical, Regulatory, Quality and Clinical Affairs for Altura Medical (Lombard Medical acquisition), Prior to that, Ziad held several senior positions including Vice-President, Regulatory, Quality and Clinical Affairs at Auxogyn (Progyny Merger) and Avinger (IPO (AVGR) NASDAQ). Past positions include Director positions with Codman (J&J) and Evalve (Foundry Group incubation – Abbott acquisition) and Guidant (Abbott acquisition). Ziad received both a BS and BA from McGill University and a J.D. from Rutgers University.
Anne-Charlotte joined Biomodex in 2019 as Group Finance Director. Anne-charlotte has over 15 years of progressive leadership experience driving scalable finance organizations, processes, and infrastructure in the US and in Europe. Prior to joining Biomodex, Anne-charlotte worked at SpineGuard (Euronext Growth Paris: ALSGD), a medical device company based in France and the US, for 10 years. Prior to SpineGuard, Anne-Charlotte held various positions at SpineVision, Theradiag (Euronext Growth Paris: ALTER), and Dräger Medical (DAX: DRW3). She received a Degree in International Marketing and Finance from INSEEC, Paris (France) and a Bachelor of Science from Boston College.